This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Clinical features

Authoring team

For healthy individuals the infection is an unpleasant but usually self-limiting disease and patients usually recover within 2–7 days.

  • Serological studies have revealed that around 30 to 50% of influenza infections can be asymptomatic, however, this may vary depending on the characteristics of the influenza strain (1).

In mild, uncomplicated influenza, after an incubation period of between one and four days, there is an abrupt onset of:

  • fever – usually it ranges between 38–40°C, the peak occurs within 24 hours of onset and lasts for 3 days
  • malaise
  • headache
  • chills
  • cough – generally dry but may be productive in some cases
  • myalgia – mainly the back and the limbs
  • extreme fatigue
  • nasal congestion
  • sore throat
  • anorexia
  • gastrointestinal symptoms – such as vomiting and diarrhoea are uncommon (10%) in adults (1,2)

Symptoms may vary in infants and children and may include fatigue, irritability, diarrhoea and vomiting (3).

After three to seven days the fever ceases and illness typically resolves although cough, malaise and lassitude may persist for a longer period (2).

Although the infection is usually self limiting it may cause complications such as primary influenza viral pneumonia, exacerbation of underlying medical conditions (e.g., pulmonary or cardiac diseases) and co-infections with other viral or bacterial pathogens (4).

Reference:

  1. Immunisation Against Infectious Disease - "The Green Book". Chapter 19. Influenza (October 2020)
  2. British Infection Society; British Thoracic Society; Health Protection Agency. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. Thorax. 2007;62 Suppl 1:1-46.
  3. National Institute for Health and Clinical Excellence (NICE) 2009. Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of NICE technology appraisal guidance 58)
  4. Centers for Disease Control and Prevention (CDC). 2009-10 Influenza Prevention & Control Recommendations Clinical Signs and Symptoms of Influenza

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.